Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DK210 |
Synonyms | |
Therapy Description |
Limited information is currently available on DK210 (Sep 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DK210 | DK-210|DK 210 | Limited information is currently available on DK210 (Sep 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05704985 | Phase I | DK210 DK210 + Nivolumab Paclitaxel DK210 + Pembrolizumab Oxaliplatin Capecitabine Fluorouracil Carboplatin | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | Recruiting | USA | 0 |